Literature DB >> 1281645

Possible regulatory role of dynorphin A in the urinary bladder.

A Berggren1, A Dahlström, A Rubenson, U Sillén.   

Abstract

UNLABELLED: Muscle strips from rat and human detrusor were studied using indirect immunofluorescence and electrical nerve stimulation in an organ bath. Immunoreactivity towards dynorphin was observed in varicose nerve fibres in the detrusor muscle and around immunonegative nerve cell bodies in the prevesical ganglia of the rat. In vitro, dynorphin A (1-13) (10(-13)-10(-6) M) strongly facilitated detrusor contraction induced by electrical field stimulation (EFS). This facilitation was counteracted by morphine (10(-10) and 10(-8) M) and naloxone (10(-10) and 10(-8) M) in a competitive manner. The facilitation could also be counteracted by the addition of the kappa-receptor antagonist M(r) 2266 (10(-7) M). Muscarinic blockade, achieved with atropine (10(-6) M), did not alter the effect of dynorphin A (1-13). Addition of phentolamine mesylate (10(-6) M), and propranolol (10(-6) M) per se facilitated the EFS-induced contractions. Both adrenergic blockade as well as the addition of the substance P blocker spantide, counteracted the facilitating effect of dynorphin A (1-13). IN
CONCLUSION: Dynorphin A immunoreactive material was found to be present in nerves in the rat detrusor and in prevesical ganglia. Dynorphin A (1-13) facilitated the detrusor contraction, possibly via actions on kappa-opioid receptors and interaction with non-cholinergic nerves.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281645     DOI: 10.1007/BF01250516

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  34 in total

1.  Endorphins: new gut peptides with a familiar face.

Authors:  R F Ambinder; M M Schuster
Journal:  Gastroenterology       Date:  1979-11       Impact factor: 22.682

2.  Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.

Authors:  R J Sheldon; L Nunan; F Porreca
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

3.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

4.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

5.  Effects of vinblastine and colchicine on monoamine containing neurons of the rat, with special regard to the axoplasmic transport of amine granules.

Authors:  A Dahlström
Journal:  Acta Neuropathol       Date:  1971       Impact factor: 17.088

6.  Characterization of opioid receptors on isolated canine gallbladder smooth muscle cells.

Authors:  C Severi; J R Grider; G M Makhlouf
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

7.  Colocalization of dynorphin-A(1-17) and dynorphin-A(1-8) within some perikarya of rat duodenum: immunohistochemical evidence for the presence of two separate dynorphinergic systems.

Authors:  H J Wolter
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

8.  Mu receptor mediated inhibition of rat urinary bladder motility: differential antagonism by kappa agonists.

Authors:  R J Sheldon; F Porreca
Journal:  Proc West Pharmacol Soc       Date:  1987

9.  Opiate and alpha receptor antagonists block the pressor responses of conscious rats given intravenous dynorphin.

Authors:  J A Thornhill; L Gregor; W S Saunders
Journal:  Peptides       Date:  1989 Jan-Feb       Impact factor: 3.750

10.  Endogenous opioid peptides: multiple agonists and receptors.

Authors:  J A Lord; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  Nature       Date:  1977-06-09       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.